Lauren Wetzler
Overview
Explore the profile of Lauren Wetzler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ezekwe Jr E, Weskamp A, Rahim R, Makiya M, Wetzler L, Ware J, et al.
J Allergy Clin Immunol Pract
. 2024 Nov;
13(1):167-175.e6.
PMID: 39515522
Background: Hypereosinophilic syndromes (HES) are defined as hypereosinophilia with eosinophil-related clinical manifestations, some of which overlap in presentation with asthma, atopic dermatitis, eosinophilic esophagitis, and/or chronic rhinosinusitis with nasal polyps....
2.
Wetzler L, Klion A
J Allergy Clin Immunol Pract
. 2023 Nov;
12(2):530-532.e18.
PMID: 37984795
No abstract available.
3.
Khoury P, Makiya M, Rahim R, Bowman A, Espinoza D, Schiffenbauer A, et al.
J Allergy Clin Immunol
. 2023 Nov;
153(3):821-830.e6.
PMID: 37951310
Background: Episodic angioedema with eosinophilia (EAE) is a rare multilineage cyclic syndrome of unknown etiology characterized by episodes of angioedema, myalgia, fatigue, and fever that occur every 3 to 8...
4.
Makiya M, Brown T, Holland N, Wetzler L, Ware J, Khoury P, et al.
Clin Exp Allergy
. 2023 Jul;
53(10):1031-1040.
PMID: 37487654
Introduction: Although IgE-mediated food allergy (FA) and eosinophilic gastrointestinal disorders (EGID) are clinically distinct and treated differently, pathogenic effector Th2 (peTh2) cells are implicated in the pathogenesis of both FA...
5.
Pongdee T, Berry A, Wetzler L, Sun X, Thumm L, Yoon P, et al.
Acta Haematol
. 2023 Jun;
146(4):316-321.
PMID: 37285821
The imatinib-sensitive fusion gene FIP1L1::PDGFRA is the most frequent molecular abnormality identified in patients with eosinophilic myeloid neoplasms. Rapid recognition of this mutation is essential given the poor prognosis of...
6.
Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders
Makiya M, Khoury P, Kuang F, Mata A, Mahmood S, Bowman A, et al.
Allergy
. 2022 Aug;
78(1):258-269.
PMID: 35971862
Background: Biomarkers of eosinophilic disease activity, especially in the context of novel therapies that reduce blood eosinophil counts, are an unmet need. Absolute eosinophil count (AEC) does not accurately reflect...
7.
Kuang F, Sampaio de Melo M, Makiya M, Kumar S, Brown T, Wetzler L, et al.
J Allergy Clin Immunol Pract
. 2022 Mar;
10(6):1598-1605.e2.
PMID: 35283330
Background: Previous studies of targeted eosinophil biologics in eosinophilic esophagitis have yielded mixed results. Possible explanations include incomplete eosinophil depletion with anticytokine (anti-IL-5) treatments and/or irreversible fibrotic tissue changes contributing...
8.
Espinoza D, Wetzler L, Holland N, Moodley N, Ware J, Klion A, et al.
J Allergy Clin Immunol Pract
. 2022 Mar;
10(5):1371-1373.e20.
PMID: 35248766
No abstract available.
9.
Chen M, Roufosse F, Wang S, Verstovsek S, Durrani S, Rothenberg M, et al.
J Allergy Clin Immunol Pract
. 2022 Feb;
10(5):1217-1228.e3.
PMID: 35181548
Background: Treatment of hypereosinophilic syndrome (HES) often requires the use of immunomodulators with substantial side effect profiles. The emergence of biologics offers an alternative treatment modality. Objective: To examine real-world...
10.
Wetzler L, Panch S, Berry A, Klion A, Khoury P
J Allergy Clin Immunol Pract
. 2021 Jan;
9(5):2107-2108.e4.
PMID: 33476787
No abstract available.